Skip to content
Screener

BioCryst Pharmaceuticals BCRX EBITDA

EBITDA at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$98.16M-169%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$109.2M+13.2%
Precigen logo
PrecigenPGEN
-$4.9M+77.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$67M+32.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio2.3×+0.1×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

$98.5Mebit+
$513.0KDepreciation Depletion & Amortization
=$98.98M

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300

FAQ

What is BioCryst Pharmaceuticals's EBITDA?
BioCryst Pharmaceuticals (BCRX) reported EBITDA of $98.98M in Q2 2026.
How has BioCryst Pharmaceuticals's EBITDA changed year-over-year?
BioCryst Pharmaceuticals's EBITDA increased by 228.7% year-over-year, from $30.12M to $98.98M.
What is the long-term trend for BioCryst Pharmaceuticals's EBITDA?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's EBITDA has grown at a 17.9% compound annual growth rate (CAGR), from -$176.94M to $342.38M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about BioCryst Pharmaceuticals's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude